New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 11.2mg equivalent to octreotide 10 mg;   - powder for injection - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 22.4mg equivalent to octreotide 20 mg;   - powder for injection - 20 mg - active: octreotide acetate 22.4mg equivalent to octreotide 20 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 33.6mg equivalent to octreotide 30 mg;   - powder for injection - 30 mg - active: octreotide acetate 33.6mg equivalent to octreotide 30 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - octreotide acetate - pdr+solv for susp for inj - 10 milligram - somatostatin and analogues

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - octreotide acetate - pdr+solv for susp for inj - 20 milligram - somatostatin and analogues

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - octreotide acetate - pdr+solv for susp for inj - 30 milligram - somatostatin and analogues

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - octreotide acetate - powder and solvent for suspension for injection - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - octreotide acetate - powder and solvent for suspension for injection - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - octreotide acetate - powder and solvent for suspension for injection - 30mg

Malta - English - Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - octreotide - powder and solvent for suspension for injection - octreotide 10 mg - pituitary and hypothalamic hormones and analogues